XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
 3 Months Ended 12 Months Ended
Dec. 31, 2023
shares
Dec. 31, 2023
shares
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
Director and Executive Officer Adoption of 10b5-1 Plans

Our Section 16 officers and directors may enter into plans or arrangements for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act. Such plans and arrangements must comply in all respects with our insider trading policies, including our policy governing entry into and operation of 10b5-1 plans and arrangements.
During the quarter ended December 31, 2023: the following Section 16 officers and directors adopted Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K of the Exchange Act); and no plans were modified or terminated. All plans adopted covered sales of Madrigal common stock (including sales of Madrigal common stock following exercise of stock options).
Name of Director or Section 16 Officer
Title of Director or Section 16 Officer
Date of Adoption, Modification, or TerminationDuration of the PlanAggregate Number of Shares of Common Stock that may be Sold under the Plan
Becky Taub, MD
President of R&D, CMO and Director
11/27/2023April 3, 202576,564
Kenneth Bate
Director
11/16/2023June 27, 202432,489
James Daly
Director
11/16/2023June 27, 202432,489
Paul Friedman, MD
Director
11/27/2023April 3, 2025100,000
Richard Levy, MD
Director
11/30/2023June 16, 202526,000
Rule 10b5-1 Arrangement Adopted true  
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Becky Taub [Member]    
Trading Arrangements, by Individual    
Name Becky Taub, MD  
Title President of R&D, CMO and Director  
Adoption Date 11/27/2023  
Termination Date April 3, 2025  
Arrangement Duration 493 days  
Aggregate Available 76,564 76,564
Kenneth Bate [Member]    
Trading Arrangements, by Individual    
Name Kenneth Bate  
Title Director  
Adoption Date 11/16/2023  
Termination Date June 27, 2024  
Arrangement Duration 224 days  
Aggregate Available 32,489 32,489
James Daly [Member]    
Trading Arrangements, by Individual    
Name James Daly  
Title Director  
Adoption Date 11/16/2023  
Termination Date June 27, 2024  
Arrangement Duration 224 days  
Aggregate Available 32,489 32,489
Paul Friedman [Member]    
Trading Arrangements, by Individual    
Name Paul Friedman, MD  
Title Director  
Adoption Date 11/27/2023  
Termination Date April 3, 2025  
Arrangement Duration 493 days  
Aggregate Available 100,000 100,000
Richard Levy [Member]    
Trading Arrangements, by Individual    
Name Richard Levy, MD  
Title Director  
Adoption Date 11/30/2023  
Termination Date June 16, 2025  
Arrangement Duration 564 days  
Aggregate Available 26,000 26,000